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Abstract. 
 
Cytosolic phospholipase A
 
2
 
 (cPLA
 
2
 
) medi-
ates agonist-induced arachidonic acid release, the ﬁrst 
step in eicosanoid production. cPLA
 
2
 
 is regulated by 
phosphorylation and by calcium, which binds to a C2 
domain and induces its translocation to membrane. The 
functional roles of phosphorylation sites and the C2
domain of cPLA
 
2
 
 were investigated. In Sf9 insect cells 
expressing cPLA
 
2
 
, okadaic acid, and the calcium-mobi-
lizing agonists A23187 and CryIC toxin induce arachi-
donic acid release and translocation of green ﬂuores-
cent protein (GFP)-cPLA
 
2
 
 to the nuclear envelope. 
cPLA
 
2
 
 is phosphorylated on multiple sites in Sf9 cells; 
however, only S505 phosphorylation partially contrib-
utes to cPLA
 
2
 
 activation. Although okadaic acid does 
not increase calcium, mutating the calcium-binding res-
idues D43 and D93 prevents arachidonic acid release 
and translocation of cPLA
 
2
 
, demonstrating the require-
ment for a functional C2 domain. However, the D93N 
mutant is fully functional with A23187, whereas the 
D43N mutant is nearly inactive. The C2 domain of 
cPLA
 
2
 
 linked to GFP translocates to the nuclear enve-
lope with calcium-mobilizing agonists but not with oka-
daic acid. Consequently, the C2 domain is necessary 
and sufﬁcient for translocation of cPLA
 
2
 
 to the nuclear 
envelope when calcium is increased; however, it is re-
quired but not sufﬁcient with okadaic acid.
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T
 
HE
 
 85-kD cytosolic phospholipase A
 
2
 
 (cPLA
 
2
 
)
 
1
 
 plays
an important role in agonist-induced arachidonic
acid release (Clark et al., 1995; Leslie, 1997). This is
a tightly regulated process since the availability of free
arachidonic acid controls the level of eicosanoid produc-
tion. The oxygenated metabolites of arachidonic acid, in-
cluding leukotrienes, prostaglandins, and thromboxanes,
have important roles in normal homeostasis and acute in-
 
flammation. An essential role for cPLA
 
2
 
 in reproductive
function and inflammation has been confirmed recently
from studies using cPLA
 
2
 
-deficient mice (Bonventre et al.,
1997; Uozumi et al., 1997). cPLA
 
2
 
 is regulated posttransla-
tionally by phosphorylation and by calcium (Channon and
 
Leslie, 1990; Clark et al., 1991, 1995; Lin et al., 1993; Qiu
et al., 1993; Leslie, 1997). Phosphorylation of cPLA
 
2
 
 on
S505 by mitogen-activated protein kinases has been shown
to be required for agonist-induced arachidonic acid re-
lease in some cell models but not in others (Lin et al.,
1993; Kramer et al., 1996; Qiu et al., 1998). A critical step
 
in the regulation of cPLA
 
2
 
 is its translocation from cyto-
sol to membrane for access to phospholipid (Channon
and Leslie, 1990; Clark et al., 1990). In several cell mod-
 
els cPLA
 
2
 
 has been shown to translocate primarily to
the nuclear envelope and endoplasmic reticulum, where
5-lipoxygenase and cyclooxygenase also localize (Glover et
al., 1995; Schievella et al., 1995; Sierra-Honigmann et al.,
1996; Hirabayashi et al., 1999). The amino terminus of
cPLA
 
2
 
 contains a C2 domain, which mediates the calcium-
dependent binding of cPLA
 
2
 
 to membrane and phospho-
lipid vesicles (Nalefski et al., 1994). C2 domains were orig-
inally described in protein kinase C (PKC) and now have
been identified in 
 
.
 
60 proteins (Nalefski and Falke, 1996;
Rizo and Südhof, 1998). They are involved in the calcium-
dependent association of proteins to membrane or in
membrane trafficking, although the function of all C2 do-
mains is not known. The C2 domain of cPLA
 
2
 
 is a 
 
b
 
-sand-
wich structure that binds two ions of calcium and preferen-
tially interacts with phosphocholine headgroups (Hixon et
al., 1998; Nalefski et al., 1998; Perisic et al., 1998; Xu et al.,
1998; Bittova et al., 1999). An increase in intracellular
calcium promotes translocation of cPLA
 
2
 
 to membrane,
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1. 
 
Abbreviations used in this paper:
 
 cPLA
 
2
 
, cytosolic phospholipase A
 
2
 
;
GFP, green fluorescent protein; HSA, human serum albumin; PKC, pro-
tein kinase C; Sf9, 
 
Spodoptera frugiperda
 
. 
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which is an important regulatory step necessary for associ-
ation of the catalytic domain of cPLA
 
2
 
 with phospholipid
substrate.
In macrophages, we have demonstrated that a transient
increase in calcium and phosphorylation of cPLA
 
2
 
 on S505
by mitogen-activated protein kinase can act together to
fully activate cPLA
 
2
 
 leading to arachidonic acid release
(Qiu et al., 1998). However, neither of these events alone
is sufficient for activation. There are also alternative path-
ways for regulating cPLA
 
2
 
 activation in the macrophage
model since both PMA and okadaic acid induce arachi-
donic acid release without increasing intracellular calcium
(Qiu et al., 1998). We have used the baculovirus expres-
sion system in insect cells to study regulation of cPLA
 
2
 
 (de
Carvalho et al., 1996). This model is now being used not
only as a source of recombinant proteins but also to study
the function of proteins and their role in signal transduc-
tion (Stancato et al., 1993, 1997; Chefalo et al., 1994). Sim-
ilar to macrophages, 
 
Spodoptera frugiperda
 
 (Sf9) cells ex-
pressing cPLA
 
2
 
 release arachidonic acid in response to
A23187 and okadaic acid (de Carvalho et al., 1996). cPLA
 
2
 
is phosphorylated on multiple sites when expressed in Sf9
cells, and phosphorylation on S727 is preferentially in-
duced by okadaic acid (de Carvalho et al., 1996). Okadaic
acid also induces phosphorylation of the S727-containing
tryptic peptide in mouse peritoneal macrophages and hu-
man monocytes (de Carvalho et al., 1996; Qiu et al., 1998).
Phosphorylation of cPLA
 
2
 
 on S505 and S727 also occurs in
thrombin- and collagen-stimulated platelets and cytokine-
stimulated HeLa cells (Börsch-Haubold et al., 1998). The
mechanisms involved in regulating the translocation of
cPLA
 
2
 
 to membrane in response to agonists that do not in-
crease intracellular calcium, and the preferential targeting
of cPLA
 
2
 
 to the nuclear envelope are not understood. The
role of these novel phosphorylation sites and the C2 do-
main in regulating cPLA
 
2
 
 translocation and arachidonic
acid release in Sf9 cells in response to okadaic acid and the
calcium-mobilizing agonists was investigated.
 
Materials and Methods
 
Reagents
 
Sf9 cells, the transfer vector pVL1393, and the TA cloning kit were ob-
tained from Invitrogen. Grace’s insect cell culture medium was obtained
from JRH Biosciences. The transfer vectors BioGreen-His and pAc-
GHLT-A, as well as baculovirus linearized DNA (BaculoGold), were
from PharMingen. Yeastolate was obtained from Becton Dickinson. Lac-
talbumin hydrolysate, penicillin (10,000 U/ml)/streptomycin (10,000 
 
m
 
g/
ml)/
 
L
 
-glutamine (29.2 mg/ml) solution, and a human spleen SuperScript
cDNA library were from Life Technologies. FBS was purchased from
Gemini Bioproducts. Human serum albumin (HSA) was from Inter-
gen Co. [5,6,8,9,11,12,14,15-
 
3
 
H]Arachidonic acid (sp act 100 Ci/mmol),
1-
 
O
 
-hexadecyl-2-[
 
3
 
H]arachidonyl-phosphatidylcholine (200 Ci/mmol),
and 
 
L
 
-1-[1-
 
14
 
C]palmitoyl-2-lysophosphatidylcholine (55 mCi/mmol) were
from DuPont/NEN. Anti–rabbit horseradish peroxidase–linked F(ab
 
9
 
)
 
2
 
IgG fragment, reagents for enhanced chemiluminescence detection on im-
munoblots, and glutathione–Sepharose beads were purchased from Am-
ersham Pharmacia Biotech. Calcium ionophore A23187 and pluronic acid
F-68 (10% solution) were obtained from Sigma Chemical Co. Ionomycin
was from Calbiochem-Novabiochem. Okadaic acid (ammonium salt) was
from Alexis Biochemicals. Fura-2 acetoxymethyl ester (AM) and the nu-
clear dye Hoechst 33342 were obtained from Molecular Probes. A donkey
anti–rabbit IgG antibody conjugated to Cy3 was obtained from Jackson
ImmunoResearch. Reagents for protein determination by the bicincho-
ninic acid method were from Pierce Chemical Co. 
 
Bacillus thuringiensis
 
d
 
-endotoxin CryIC was generously provided by Dr. Jean-Louis Schwarz
(National Research Council, Montreal, Canada) and Dr. Marianne Carey
(Case Western Reserve University, Cleveland, OH).
 
Preparation of DNA Constructs
 
The DNA encoding for human cPLA
 
2
 
 (provided by Dr. James Clark, Ge-
netics Institute, Cambridge, MA) was cloned into the transfer vector
pVL1393 as previously described (de Carvalho et al., 1993). For fusion-
protein construction, the human cPLA
 
2
 
 coding region was obtained by
PCR from a human spleen cDNA library and cloned into the pCR2.1 vec-
tor following the TA cloning method. The PCR primers used were 5
 
9
 
-
GGATCCTGACTGAAAGCTAGAGGC-3
 
9
 
 (bases 22–45; GenBank ac-
cession number M72393) and 5
 
9
 
-CAGCCAGTCTCTCATGATCAG-
TACGAC-3
 
9
 
 (bases 2475–2501). Two in-frame codons present in the 5
 
9
 
untranslated region were removed by PCR amplification using the prim-
ers 5
 
9
 
-GAGAGCGGGTACCCCGGTTTGAAGTGTGAAAACATTT-
CCTG-3
 
9
 
 (which contains a KpnI restriction site) and 5
 
9
 
-CCTGAT-
TAGGATCCAAAATAAATTCAAAGGTCTC-3
 
9
 
 (which straddles a
BamHI site). The PCR product was cut with KpnI and BamHI and cloned
into pCR2.1 containing the cPLA
 
2
 
 gene. The modified cPLA
 
2
 
 sequence
was cloned into the transfer vectors pAcGHLT (for expression of GST-
cPLA
 
2
 
) and BioGreen-His (for expression of green fluorescent pro-
tein [GFP]-cPLA
 
2
 
) using the SacI and PstI sites. Different mutants of
cPLA
 
2
 
 were obtained by site-directed mutagenesis using a kit from
5Prime
 
®
 
3Prime Inc., following the manufacturer’s instructions. The mu-
tagenic oligonucleotides used were 5
 
9
 
-CTTGATACTCCAAATCCC-
TATGTG-3
 
9
 
 (D43N), 5
 
9
 
-CGTTAATGAATGCCAATTATG-3
 
9
 
 (D93N),
5
 
9
 
-GATAGCTCGGACGCTGATGATGAATCAC-3
 
9
 
 (S437A), 5
 
9
 
-GAA-
GATGCTGGAGCTGACTATCAAAGTG-3
 
9
 
 (S454A), 5
 
9
 
-CTTATCC-
ACTGGCTCCTTTGAG-3
 
9
 
 (S505A), and 5
 
9
 
-CCATCTCGTTGCGCTG-
TTTCCC-3
 
9
 
 (S727A). A truncated version of cPLA
 
2 
 
(
 
D
 
721–749) was
generated by introducing a stop codon after amino acid 720 using the
mutagenic oligonucleotide 5
 
9
 
-GAATATAGAAGATAGAATCCATC-
TCG-3
 
9
 
. A GFP-C2 construct was generated by using the oligonucleotide
5
 
9
 
-GCCCAGACCTATGATTTAGTATGGC-3
 
9
 
 to insert a stop codon
after amino acid 144. All mutations were confirmed by sequencing of
DNA from several bacterial colonies selected on agar plates.
 
Cell Culture and Generation of Recombinant 
Baculovirus Stocks
 
Sf9 cells were routinely cultured in 100-ml vented spinner flasks, at 27
 
8
 
C,
in TNM-FH medium (Grace’s medium supplemented with 3.3 g/liter yeast-
olate, 3.3 g/liter lactalbumin hydrolysate, and 1% penicillin/streptomycin/
glutamine solution) containing 10% FBS and 0.1% pluronic acid. Cell
density was maintained at 0.2–1.5 
 
3
 
 10
 
6
 
 cells/ml. Recombinant baculovi-
rus was generated by cotransfection of Sf9 cells with the transfer vector
pVL1393 containing the gene for cPLA
 
2
 
 and linearized baculovirus DNA
(BaculoGold; PharMingen) following the manufacturer’s instructions. Vi-
ral stocks derived from single virus particles were obtained by plaque pu-
rification and amplified (two cycles) following standard procedures. The
titer of the working viral stocks was determined by infecting cells with se-
rial dilutions of the stocks, overlaying them with agarose-containing
TNM-FH medium, and counting the plaques after 4–6 d of incubation.
 
Measurement of Intracellular Calcium Concentration
 
Sf9 cells were plated on glass coverslips (13 mm diam) in 24-well plates
(4 
 
3
 
 10
 
5
 
 cells/well) and infected with baculovirus containing wild-type
cPLA
 
2
 
. After infection (50–54 h), Sf9 cells were washed three times in
buffer A (10 mM 2-[
 
N
 
-morpholino]ethanesulfonic acid, 10 mM NaCl, 60
mM KCl, 25 mM MgCl
 
2
 
, 4 mM 
 
D
 
-glucose, 110 mM sucrose, adjusted to pH
6.2 with Trizma base) and incubated with 2 
 
m
 
M Fura-2 AM (in buffer A)
for 60 min at room temperature protected from light. The cells were
rinsed twice with buffer A, positioned in a fluorometer cuvette, and main-
tained at 27
 
8
 
C with continuous stirring. Calcium chloride or EGTA was
added to buffer A to reach the final concentrations indicated in the fig-
ures. The effect of agonists on the intracellular concentration of calcium
was determined by spectrofluorometry as previously described (Qiu et al.,
1998).
 
Arachidonic Acid Release
 
Sf9 cells were plated in 24-well tissue culture plates (2.5 
 
3
 
 10
 
5
 
 cells/well)
and infected with baculovirus. After infection (30–35 h), they were labeled 
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with 0.2 
 
m
 
Ci/well [
 
3
 
H]arachidonic acid and incubated overnight (16–18 h).
The cells were washed three times with TNM-FH medium containing
0.1% HSA to remove unincorporated arachidonic acid and then treated
with agonists. After stimulation, the medium was centrifuged at 500 
 
g
 
 for
10 min, and the amount of radioactivity in the supernatant was deter-
mined by scintillation counting. Cells were scraped in 0.5 ml of 0.1% Tri-
ton X-100 for determining the total cellular radioactivity. For immunoblot
analysis of cPLA
 
2
 
, Sf9 cells were scraped in 100 
 
m
 
l of Laemmli buffer and
the protein concentration was determined. DTT was added to a final con-
centration of 25 mM, and samples were boiled for 5 min before loading
(0.5 
 
m
 
g/lane) on a SDS-polyacrylamide gel (Qiu et al., 1998). After elec-
trophoresis, proteins were transferred to nitrocellulose and cPLA
 
2
 
 was de-
tected by chemiluminescence using a 1:5,000 dilution of polyclonal antise-
rum to cPLA
 
2
 
 (de Carvalho et al., 1993; Qiu et al., 1998).
 
Phospholipase A
 
2
 
 Assay
 
Sf9 cells (1.25 
 
3
 
 10
 
6
 
 cells/35 mm dish) were infected with recombinant
baculovirus for 48–50 h. The monolayers were rinsed with 2 ml of PBS and
scraped into 100 
 
m
 
l of ice-cold homogenization buffer (10 mM Hepes, pH
7.4, 1 mM EGTA, 0.34 M sucrose, 10% glycerol, 10 
 
m
 
g/ml leupeptin, 10
 
m
 
g/ml aprotinin, and 1 mM PMSF). Cells were lysed with a probe sonica-
tor (3 times for 5 s, then 2 times for 10 s) on ice, and the homogenates cen-
trifuged at 100,000
 
 g 
 
for 1 h. The protein concentration in the cytosols was
determined and then DTT was added to a final concentration of 1 mM.
The cytosols were kept on ice and assayed within 24 h, or stored at 
 
2
 
20
 
8
 
C
and thawed just before the assay. The PLA
 
2
 
 and lysophospholipase activi-
ties of cPLA
 
2
 
 were determined by using 1-
 
O
 
-hexadecyl-2-[
 
3
 
H]arachido-
nylphosphatidylcholine (final concentration 30 
 
m
 
M), or [1-
 
14
 
C]palmitoyl-
2-lysophosphatidylcholine (50 
 
m
 
M), respectively, as previously described
 
(de Carvalho et al., 1995). Reactions were started with the addition of cy-
tosolic protein (10 
 
m
 
g for PLA
 
2
 
 assays, 5 
 
m
 
g for lysophospholipase assays),
and proceeded for 5 min at 37
 
8
 
C. Equal expression of the mutant enzymes
was verified by immunoblotting and quantitation of the cPLA
 
2
 
 bands us-
ing a Storm 840 system from Molecular Dynamics.
 
Affinity Purification of cPLA
 
2 Antibody
Sf9 cells grown in suspension (6 3 108 cells in 600 ml medium) were in-
fected with baculovirus encoding the fusion protein GST-cPLA2. Cells
were lysed in 20 mM Hepes, pH 7.4, containing 2 mM EGTA, 1% Triton
X-100, 10% glycerol, 1 mM PMSF, 10 mg/ml leupeptin, and 10 mg/ml apro-
tinin. Lysates were incubated with 200 ml glutathione–Sepharose beads for
2 h at 48C. The beads were washed sequentially with 2 ml each of 10 mM
Tris (pH 7.5), 10 mM Tris (pH 8.8), 100 mM triethylamine (pH 11.5), and
10 mM Tris (pH 7.5). The beads were mixed with rabbit anti-cPLA2 anti-
serum (500 ml, diluted 1:9 in 10 mM Tris, pH 7.5), and then washed with 2 ml
each of 10 mM Tris (pH 7.5), 0.5 M NaCl in 10 mM Tris (pH 7.5), and 10 mM
Tris (pH 8.8). Antibody was eluted with 2 ml of 100 mM triethylamine
(pH 11.5) into tubes containing 1 M Tris (pH 8.0) to adjust the pH.
Microscopy
For microscopy experiments, 1.25 3 106 cells were plated on 35-mm tissue
culture dishes and infected with baculovirus containing the genes for the
different GFP-containing fusion constructs at multiplicities of infection
ranging from 2 to 10 colony forming units per cell. After infection (40–50 h),
cells were washed twice with TNM-FH medium and observed at room
temperature using an Olympus Vanox-T Microscope equipped with an
Achroplan 63X Zeiss lens and a FITC filter. Digital confocal images were
Figure 1. CryIC toxin–induced arachi-
donic acid release and calcium mobili-
zation in Sf9 cells expressing cPLA2.
Sf9 cells were infected with recombi-
nant baculovirus containing transfer
vector pVL1393 alone (Vector Con-
trol) or the gene for human cPLA2. Af-
ter infection (50–54 h), cells were
prelabeled with [3H]arachidonic acid
and then incubated for 20 min with the
indicated concentrations of CryIC
toxin (A) or with 2 mg/ml CryIC toxin
or vehicle (Unstimulated), for the
times indicated (B). The amount of
[3H]arachidonic acid released into the
medium is expressed as a percentage of
the total radioactivity incorporated
(cell-associated plus medium). Data
represent the average 6 SD of a repre-
sentative experiment and were verified
in at least three independent experi-
ments performed in triplicate. (C) Cal-
cium mobilization was measured in
Fura-2 AM–loaded Sf9 cells expressing
cPLA2 after addition (indicated by the
arrow) of ionomycin (1 mM), okadaic
acid (1 mM), or CryIC toxin (2 mg/ml).
The intracellular calcium concentra-
tion was monitored over time by re-
cording the excitation spectra at 340
and 380 nm. The extracellular calcium
concentration was 9 mM. Results
shown are from a representative exper-
iment and were verified in at least
three independent experiments.The Journal of Cell Biology, Volume 145, 1999 1222
obtained with a SpectraSource Orbis 16 camera, using Slidebook software
from Intelligent Imaging Innovations, Inc. Images shown in the figures are
representative of at least three independent experiments.
For immunofluorescence, Sf9 cells (2.5 3 105) were plated on 13-mm
glass coverslips in 24-well culture plates and infected with baculovirus
containing cPLA2. After infection (40–50 h), cells were rinsed twice with
0.5 ml PBS, pH 7.5, and then fixed for 15 min with 0.5 ml 3% paraformal-
dehyde in PBS containing 3% sucrose. After rinsing with PBS, cells were
permeabilized with 0.2% Triton X-100 for 15 min, and then incubated for
30 min with HBSS containing 10% FBS (blocking solution). Cells were in-
cubated for 2 h with affinity-purified anti-cPLA2 antibody diluted 1:20 in
blocking solution. After extensive rinsing with PBS, cells were incubated
for 1 h with donkey anti–rabbit IgG antibody conjugated to Cy3 (10 mg/ml
in blocking solution). Coverslips were mounted on microscope slides in
0.1 M Tris-HCl, pH 8.5, containing 90% glycerol and 2 mg/ml orthophe-
nylenediamine. Cells were observed by digital confocal microscopy using
a Cy3 filter.
Results
Arachidonic Acid Release and Calcium Mobilization in 
Sf9 Cells Expressing cPLA2
Sf9 cells expressing cPLA2 release arachidonic acid in re-
sponse to A23187 and okadaic acid (de Carvalho et al.,
1996). We have found that CryIC toxin from Bacillus thur-
ingiensis also stimulates arachidonic acid release from Sf9
cells expressing cPLA2, but not from cells infected with
baculovirus containing the vector alone (Fig. 1 A). The
crystal (Cry) protein toxins are inclusions formed by the
gram-positive soil bacterium during sporulation. CryIC
toxin has been shown to induce an increase in intracellular
calcium in Sf9 cells, probably in a receptor-mediated fash-
ion (Schwartz et al., 1991). A 40-kD binding protein for
CryIC toxin has been identified recently (Kwa et al.,
1998). Arachidonic acid release in response to CryIC toxin
was near maximal at 2 mg/ml, a concentration well below
the ED50 for toxicity (15 mg/ml) for Sf9 cells (Monette et al.,
1997). Rapid and prolonged release of arachidonic acid
was induced by CryIC toxin (Fig. 1 B).
An increase in intracellular calcium is an important
mechanism for regulating cPLA2 by promoting its translo-
cation and binding to membrane. However, we demon-
strated previously that okadaic acid induces arachidonic
acid release in macrophages without increasing intracellu-
lar calcium (Qiu et al., 1998). Experiments were carried
out to determine the effect of okadaic acid on intracellular
calcium levels in the Sf9 model in comparison to ionomy-
cin and CryIC, which are known to increase intracellular
calcium. As shown in Fig. 1 C, okadaic acid did not pro-
mote an increase in intracellular calcium in Sf9 cells ex-
pressing cPLA2, and no effect was seen when the incuba-
tion was prolonged for as long as 30 min. In contrast,
CryIC toxin induced an increase in intracellular calcium
that did not occur as rapidly as with ionomycin, but did
reach a similar level. As previously reported, the increase
in intracellular calcium induced by CryIC was sustained
for at least 15 min (not shown) (Schwartz et al., 1991).
Agonist-induced Translocation of GFP-cPLA2 to the 
Nuclear Envelope in Sf9 Cells
GFP was linked to the amino terminus of cPLA2 and its
subcellular localization was visualized in living Sf9 cells.
GFP-cPLA2, like GFP alone, was uniformly distributed
throughout unstimulated cells when observed in different
planes of the cell by confocal analysis (data not shown).
In Sf9 cells treated with the calcium-mobilizing agonists
A23187 and CryIC toxin, as well as okadaic acid, the GFP-
cPLA2 fusion protein exhibited time-dependent transloca-
tion to the nuclear envelope (Fig. 2). Translocation was
evident in at least 80–85% of the cells observed in each ex-
Figure 2. Agonist-induced transloca-
tion of GFP-cPLA2, but not GFP
alone, to the nuclear envelope in living
Sf9 cells. Sf9 cells expressing GFP-
cPLA2 were incubated with 2 mg/ml
A23187, 2 mg/ml CryIC toxin, or 1 mM
okadaic acid. Digital confocal images
were obtained at the times indicated
(in minutes). The bottom two series
show images of Sf9 cells expressing
GFP alone at different times after ad-
dition of CryIC toxin (in minutes), or
at 30 min after addition of A23187
(bottom left) or okadaic acid (bottom
right).Gijn et al. Regulation of Cytosolic PLA2 1223
periment. Diffuse fluorescence emanating from the nu-
clear envelope could also be observed and may represent
cPLA2 bound to endoplasmic reticulum. cPLA2 that is
present both inside the nucleus and in the cytosol in un-
stimulated cells translocated to the nuclear envelope. Im-
portantly, GFP alone did not translocate in response to
agonist treatment and remained uniformly distributed.
Translocation of GFP-cPLA2 to the nuclear envelope was
evident by 5–10 min after treatment with the agonists and
was nearly complete by 20–30 min (Fig. 2). The time
course of translocation was not identical from cell to cell in
the population and could vary by minutes. As previously
reported the agonists induce significant arachidonic acid
release by 15 min, which is consistent with the time course
of translocation (Fig. 1 B) (de Carvalho et al., 1996).
To further substantiate that GFP-cPLA2 localizes at the
nuclear envelope, Sf9 cells expressing GFP-cPLA2 were
treated with the nuclear dye Hoechst 33342. As shown in
Fig. 3 A, GFP-cPLA2 was uniformly distributed through-
out the cell, whereas the Hoechst localized to the nucleus.
When GFP-cPLA2 and Hoechst colocalized, as seen inside
the nucleus of the unstimulated cell, the purple color was
diminished and the fluorescence appears white. As shown
in the cell treated with A23187, GFP-cPLA2 localized to
the nuclear envelope and the perinuclear region, whereas the
purple Hoechst stain remained distributed throughout the
nucleus. When the GFP-cPLA2 and Hoechst fluores-
cence were visualized together a bright ring of GFP-
cPLA2 was seen surrounding the purple nucleus in the
stimulated cell.
To verify that the translocation of cPLA2 was not influ-
enced by the GFP moiety, cPLA2 was expressed alone and
as a GFP fusion protein in Sf9 cells and visualized by im-
munofluorescence using affinity-purified polyclonal anti-
cPLA2 antibody. Localization of cPLA2 was similar to
GFP-cPLA2 in fixed Sf9 cells (Fig. 3 B). In unstimulated
cells, the enzyme was uniformly distributed throughout
the cell. In response to A23187, cPLA2 and GFP-cPLA2
similarly translocated to the nuclear envelope and perinu-
clear region. Experiments were also carried out to verify
that the GFP-cPLA2 fusion protein was catalytically active
in Sf9 cells and could mediate agonist-induced arachidonic
acid release. As shown in Fig. 3 C, cells expressing either
cPLA2 or GFP-cPLA2 released arachidonic acid to a simi-
lar extent in response to A23187 and okadaic acid. GFP-
cPLA2 exhibited a decrease in electrophoretic mobility
(gel shift) in response to okadaic acid, as occurs with the
native enzyme (Fig. 3 C) (de Carvalho et al., 1996).
Figure 3. Translocation of
cPLA2 and GFP-cPLA2 to
the nuclear envelope in living
and fixed Sf9 cells. (A) Sf9
cells expressing GFP-cPLA2
were incubated for 20 min
with the nuclear dye Hoechst
33342 (10 mg/ml), and then
treated with vehicle (0.1%
DMSO; US) or 2 mg/ml
A23187 for 15 min. Digital
confocal images of living Sf9
cells were obtained with a
FITC filter to visualize the
fluorescence from GFP
(shown in green, left) or a
UV filter for Hoechst (shown
in purple, middle). A com-
bined image showing the sig-
nals from both fluorophores
is shown on the right. (B) Sf9
cells expressing cPLA2 or
GFP-cPLA2 were treated
with vehicle or 2 mg/ml
A23187 for 20 min. Proteins
were visualized by immuno-
fluorescence in fixed cells us-
ing an affinity-purified anti-
cPLA2 antibody, and images
were obtained by digital
confocal microscopy. (C)
[3H]Arachidonic acid re-
lease from Sf9 cells express-
ing cPLA2 or GFP-cPLA2
was measured after treat-
ment with vehicle, 2 mg/ml A23187, or 1 mM okadaic acid for 90 min at room temperature. The data shown are average 6 SD from a
representative experiment of at least three performed in triplicate. The inset shows an immunoblot of cPLA2 from unstimulated and
okadaic acid–treated Sf9 cells.The Journal of Cell Biology, Volume 145, 1999 1224
Arachidonic Acid Release in Sf9 Cells Expressing 
Phosphorylation Site Mutants of cPLA2
We reported previously that treatment of Sf9 cells with
okadaic acid increases phosphorylation of cPLA2 on S727
and to a lesser extent on S437, S454, and S505 (de Car-
valho et al., 1996). To determine if phosphorylation of
these sites was functionally important for okadaic acid–
induced arachidonic acid release, the serines were mutated
to alanines and the mutant cPLA2 constructs expressed in
Sf9 cells. A double mutant construct, S505A/S727A, was
also generated since both sites may act cooperatively in
regulating cPLA2. In addition, a carboxy-terminal deletion
(D721–749) was produced to avoid the possibility that
serines near S727 (S724, S729, and S731) may become
phosphorylated when S727 is converted to an alanine. Sf9
cells expressing the S727A, S437A, or S454A mutant con-
structs exhibited the same magnitude of arachidonic acid
release in response to A23187, CryIC toxin, and okadaic
acid as Sf9 cells expressing wild-type cPLA2 (Fig. 4). These
results demonstrate that phosphorylation of these sites
does not play a functional role in cPLA2 activation in this
model. cPLA2 containing the S505A substitution was the
only phosphorylation site mutant that was less effective
(by 50%) at mediating arachidonic acid release. The re-
sults with cells expressing cPLA2 containing either the
S505A/S727A double mutation or the S505A single muta-
tion were not significantly different. Arachidonic acid re-
lease from Sf9 cells expressing the carboxy-terminal dele-
tion mutant was no different from the response of Sf9 cells
expressing wild-type cPLA2, confirming that phosphoryla-
tion of S727 plays no functional role in this model and that
the extreme carboxy terminus of cPLA2 is not essential.
Importantly, the level of expression of wild-type and mu-
tant forms of cPLA2 was similar (Fig. 4). All the mutant
cPLA2 enzymes except S505A were able to gel-shift in re-
sponse to okadaic acid, demonstrating that the character-
istic retardation of the electrophoretic mobility is only
due to phosphorylation of S505, and not the other sites.
A23187 and CryIC toxin have no effect on cPLA2 electro-
phoretic mobility in Sf9 cells (de Carvalho et al., 1996).
Arachidonic Acid Release in Sf9 Cells Expressing C2 
Domain Mutants of cPLA2
Although okadaic acid induces arachidonic acid release
without increasing intracellular calcium, our previous
work with macrophages has shown that resting levels of
calcium are required (Qiu et al., 1998). This suggested that
the C2 domain of cPLA2 is functionally important for reg-
ulation of the enzyme in response to okadaic acid. The
crystal structure of the cPLA2 C2 domain has revealed
several amino acid residues (D40, T41, D43, N65, D93,
A94, and N95) that participate in binding calcium, and it
has been shown recently that mutation of these residues
impairs PLA2 activity and binding of cPLA2 to phospho-
lipids (Perisic et al., 1998; Bittova et al., 1999). To deter-
mine if a functional C2 domain was required for cPLA2 to
Figure 4. Agonist-induced arachidonic acid re-
lease from Sf9 cells expressing wild-type or phos-
phorylation-site mutants of cPLA2. [3H]Arachi-
donic acid release from Sf9 cells was measured
after treatment with A23187 (2 mg/ml) or okadaic
acid (1 mM) for 90 min, or with CryIC toxin (2
mg/ml) for 20 min. The amount of label released
into the medium is expressed as a percentage of
the total radioactivity incorporated (cell-associ-
ated plus medium). Data represent the mean 6
SEM of three experiments performed in tripli-
cate. The bottom panel shows a representative
immunoblot of cPLA2.Gijn et al. Regulation of Cytosolic PLA2 1225
mediate arachidonic acid release in response to okadaic
acid compared with the calcium-mobilizing agonists, two
calcium binding residues (D43 and D93) were mutated to
asparagine residues. cPLA2 containing the D43N, D93N,
or D43N/D93N mutations was unable to mediate okadaic
acid–induced arachidonic acid release in Sf9 cells (Fig. 5).
Arachidonic acid release induced by A23187 or CryIC
toxin was also dramatically suppressed in Sf9 cells express-
ing D43N or D43N/D93N cPLA2, whereas the D93N mu-
tant was fully functional. In fact, the D93N mutant exhib-
ited a modest but reproducible increased response to
A23187, as compared with wild-type cPLA2. As shown in
the Western blot, the C2 domain mutants of cPLA2 are ex-
pressed at similar levels and gel-shifted in response to oka-
daic acid. Mutation of D93N to an asparagine resulted in
an increased electrophoretic mobility of cPLA2 (Fig. 5).
The effect of the C2 domain mutations on translocation
of GFP-cPLA2 in response to okadaic acid and the cal-
cium-mobilizing agonists was evaluated. The D43N or
D43N/D93N mutant enzymes were unable to translocate
to the nuclear envelope in living Sf9 cells treated with
A23187, whereas GFP-cPLA2 containing the D93N muta-
tion was fully functional and translocated in response to
the calcium ionophore (Fig. 6). Translocation was evident
in at least 85% of the cells observed in each experiment.
Similar results were also obtained with CryIC toxin (not
shown). In contrast, the D93N mutant did not translo-
cate to the nuclear envelope in response to okadaic acid
(Fig. 6). The D43N and D43N/D93N constructs were also
unable to translocate in response to okadaic acid (not
shown).
Role of Extracellular Calcium in Regulating 
Arachidonic Acid Release by Wild-Type and C2 
Mutants of cPLA2
The implication of the above results is that arachidonic
acid release induced by okadaic acid in Sf9 cells would
show less dependency on extracellular calcium than the re-
sponse to A23187 or CryIC toxin, but would be dependent
on resting levels of intracellular calcium. As shown in Fig.
7, depleting extracellular calcium dramatically reduced
A23187-induced arachidonic acid release from Sf9 cells
expressing wild-type cPLA2 but had less effect on cells
treated with okadaic acid. The significant effect of deplet-
ing extracellular calcium on okadaic acid–induced arachi-
donic acid release may be due to the observed decrease in
basal levels of intracellular calcium that occurs when ex-
tracellular calcium levels are decreased. In normal Sf9 me-
dium containing 9 mM calcium the intracellular calcium
concentration was 68 6 16 nM (mean 6 SEM, n 5 4), and
the level decreased to 17 6 8 nM when no calcium was
Figure 5. Arachidonic acid release from Sf9 cells expressing wild-
type or C2 domain mutants of cPLA2. [3H]Arachidonic acid re-
lease from Sf9 cells was measured after treatment with A23187 (2
mg/ml) or okadaic acid (1 mM) for 90 min, or with CryIC toxin for
20 min. Data represent the mean 6 SEM of three experiments
performed in triplicate. The bottom panel is a representative im-
munoblot of cPLA2 and the results were verified in at least three
independent experiments.
Figure 6. Effect of D43N and D93N mutations on A23187- and
okadaic acid–induced translocation of GFP-cPLA2. Sf9 cells ex-
pressing the indicated mutant constructs of GFP-cPLA2 were
treated with A23187 or okadaic acid, and the intracellular distri-
bution of GFP-cPLA2 was visualized by digital confocal micros-
copy.The Journal of Cell Biology, Volume 145, 1999 1226
added to the medium. With EGTA in the medium, intra-
cellular calcium was below the level of detection (#5 nM).
The agonist-induced level of intracellular calcium can be
manipulated by incubating Sf9 cells in medium containing
varying levels of extracellular calcium. The effect of extra-
cellular calcium concentration on the ability of CryIC
toxin to induce arachidonic acid release in Sf9 cells ex-
pressing the C2 mutant constructs of cPLA2 was evaluated
and correlated with the intracellular levels of calcium (Fig.
8 A). Arachidonic acid release induced by CryIC toxin
was dependent on extracellular calcium and decreased to
near baseline levels when it was chelated with EGTA. Sf9
cells expressing cPLA2 containing the D43N or D43N/
D93N mutations exhibited little arachidonic acid release
above baseline levels in response to CryIC toxin. The abil-
ity of cPLA2 containing the D93N mutation to mediate
arachidonic acid release when extracellular calcium was
decreased from 9 to 2 mM paralleled the response ob-
served with wild-type cPLA2, both exhibiting an z30–35%
decrease in responsiveness. In contrast, when no calcium
was added to the medium, the D93N mutant enzyme was
unable to mediate arachidonic acid release, whereas there
was still a significant response in cells expressing wild-type
cPLA2. These results demonstrate that the D43N and
D43N/D93N mutations dramatically reduce the ability of
the enzyme to mediate arachidonic acid release even at the
highest levels of intracellular calcium achieved (630 nM)
with CryIC toxin–treated Sf9 cells in medium containing
9 mM calcium. However, cPLA2 containing the D93N mu-
tation is functional at concentrations of intracellular cal-
cium in the 0.2–0.6 mM range but not at 36 nM intracellu-
lar calcium.
Calcium Differentially Affects Enzymatic Activity of C2 
Domain Mutants of cPLA2
The results of expressing the C2 domain mutants of cPLA2
in Sf9 cells suggested that mutating D43 and D93 differen-
tially affected the affinity of the enzyme for calcium. This
was verified in vitro by measuring the effect of calcium
concentration on cPLA2 activity of the mutant enzymes in
the cytosolic fraction of Sf9 cells in which equal expression
of cPLA2 was confirmed by densitometry (Fig. 8 B). Wild-
type cPLA2 exhibited significant activity at nanomolar cal-
cium that continued to increase substantially up to 1 mM
calcium with little additional increase in the millimolar
range. Consistent with the results of expressing the C2 mu-
tants in Sf9 cells, mutating D43 had a more profound ef-
fect on the calcium sensitivity of cPLA2 than mutating
D93. cPLA2 containing the D43N or D43N/D93N muta-
tions exhibited very little activity at concentrations of cal-
cium #1 mM but exhibited significant activity at millimo-
lar calcium. Unlike wild-type cPLA2, the D93N mutant did
not exhibit an increase in activity at 50 nM calcium, but did
have significant activity in the 0.25–1 mM range. At 1 mM
calcium the wild-type and D93N mutant enzymes exhib-
ited similar activities. As previously reported, cPLA2 ex-
hibits lysophospholipase activity, which is calcium inde-
pendent (Leslie, 1991; de Carvalho et al., 1995). The
lysophospholipase activity of cPLA2 containing the muta-
tions in the C2 domain was not significantly different from
wild-type cPLA2 (data not shown).
Translocation of the C2 Domain of cPLA2 to the 
Nuclear Envelope
Experiments were undertaken to determine if the C2 do-
main of cPLA2 played a role in the preferential targeting
of cPLA2 to the nuclear envelope. GFP was linked to the
amino terminus of the C2 domain and expressed in Sf9
cells. GFP-C2 was uniformly distributed throughout un-
stimulated cells as observed for GFP-cPLA2 (Fig. 9).
A23187 induced translocation of the C2 domain to the nu-
clear envelope in Sf9 cells with a similar time course as the
full-length enzyme. The same results were observed in re-
sponse to the CryIC toxin (not shown). In contrast to the
calcium-mobilizing agonists, okadaic acid did not induce
translocation of GFP-C2. Translocation of GFP-C2 to the
nuclear envelope in response to A23187 and CryIC toxin
required extracellular calcium as observed for full-length
cPLA2 (Fig. 10). The calcium-mobilizing agonists did not
induce translocation of GFP-C2 in Sf9 cells incubated in
medium containing EGTA. However, the subsequent ad-
dition of calcium to the medium resulted in translocation
of GFP-C2 to the nuclear envelope.
Discussion
Sf9 Cells as a Model for cPLA2
Structure–Function Studies
The baculovirus expression system in Sf9 insect cells is a
useful model to study the regulation of cPLA2. This system
Figure 7. Role of extracellular calcium in regulating A23187- and
okadaic acid–induced arachidonic acid release. Sf9 cells express-
ing cPLA2 were labeled with [3H]arachidonic acid and then
rinsed in calcium-free TNM-FH medium containing 0.1% HSA.
The cells were incubated in TNM-FH medium containing 0.1%
HSA with the indicated concentrations of EGTA or calcium
chloride and then treated with vehicle, A23187 (2 mg/ml), or oka-
daic acid (1 mM) for 90 min. The data (mean 6 SEM of four ex-
periments in triplicate) are expressed as a percentage of the max-
imum [3H]arachidonic acid release, which was 19.5 6 8.2% for
A23187-treated cells and 15.0 6 2.9% for okadaic acid–treated
cells. The measured percent release from unstimulated cells was
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has been used extensively to study the function of ex-
pressed proteins and their roles in signal transduction
(Mancini and Evans, 1993; Stancato et al., 1993, 1997; Che-
falo et al., 1994). The effect of cPLA2 mutations on arachi-
donic acid release and translocation can be directly com-
pared in intact, living cells. Importantly, the stimulated
arachidonic acid release is due to cPLA2 since there is lit-
tle contribution of endogenous PLA2 enzymes. The re-
sponses of Sf9 cells expressing cPLA2, such as arachidonic
acid release and phosphorylation, are similar to responses
that we have observed in murine macrophages and human
monocytes (Qiu et al., 1993; de Carvalho et al., 1996; Qiu
et al., 1998). In addition, GFP-cPLA2 is targeted to the nu-
clear envelope in response to the calcium-mobilizing ago-
nists and okadaic acid. Using the GFP fusion protein al-
lows translocation to be followed in real time in living
cells, and the GFP moiety attached to the amino terminus
of cPLA2 does not appear to influence the function of the
enzyme. It should be noted that the mechanisms involved
in the regulation of cPLA2 such as the importance of phos-
phorylation, calcium, and even the site of subcellular local-
ization, appear cell type– and agonist-dependent. Sf9 cells
are ovarian cells and may lack regulatory components
present in certain mammalian cells. However, there are
also considerable differences in the regulation of cPLA2
activation among different mammalian cell types. For ex-
ample, phorbol esters or calcium ionophores alone are
poor inducers of cPLA2 activation (and arachidonic acid
release) in many cell types, but can act synergistically.
However, in macrophages and certain hemopoietic cells
these are potent agonists. Similar to macrophages, Sf9
cells expressing cPLA2 respond to A23187 and okadaic
acid but, unlike macrophages, not to PMA.
In unstimulated Sf9 cells, the GFP-cPLA2 fusion protein
Figure 8. Differential sensitivity of
D43N and D93N C2 domain mutant
cPLA2 enzymes to calcium. (A) Corre-
lation of CryIC toxin–induced arachi-
donic acid release from Sf9 cells by C2
domain mutants of cPLA2 and intracel-
lular calcium levels. [3H]Arachidonic
acid–labeled Sf9 cells expressing wild-
type and C2 domain mutants of cPLA2
were incubated in TNM-FH medium
containing 0.1% HSA with the indi-
cated concentrations of EGTA or cal-
cium chloride, and then treated with ve-
hicle or 2 mg/ml CryIC toxin for 20 min.
The amount of [3H]arachidonic acid
released into the medium is expressed
as a percentage of the total incorpo-
rated (cell-associated plus medium).
Results shown are average 6 SD of a
representative experiment and were
verified in at least three independent
experiments. The levels of intracellular
calcium in Sf9 cells treated with CryIC
toxin are shown below the abscissa.
Fura-2 AM–loaded Sf9 cells expressing
cPLA2 were incubated in medium con-
taining the indicated concentrations of
EGTA or calcium and then treated
with 2 mg/ml CryIC toxin for 5 min.
Data shown are the mean 6 SEM of
three independent experiments. (B)
Effect of calcium concentration on the
enzymatic activity of wild-type and C2
domain mutants of cPLA2. Cytosols
were prepared from Sf9 cells express-
ing wild-type (h), D43N (e), D93N
(s), or D43N/D93N (n) cPLA2 en-
zymes and assayed for PLA2 activity at
various calcium concentrations. Re-
sults shown are average 6 SD of a rep-
resentative experiment and were veri-
fied in three independent experiments
in triplicate. Background radioactivity
(typically  ,1,000 dpm) was deter-
mined by incubating the substrates in
the absence of enzyme, and was sub-
tracted from the data.The Journal of Cell Biology, Volume 145, 1999 1228
was uniformly distributed both inside the nucleus and in
the cytosol. This distribution was not influenced by the
level of GFP-cPLA2 expression, which can be varied by
decreasing the multiplicity of infection and by decreasing
the infection time. In several unstimulated mammalian
cells, cPLA2 has been observed inside the nucleus, in the
cytosol, and in both locations depending on the cell type
and growth conditions (Glover et al., 1995; Schievella et al.,
1995; Peters-Golden et al., 1996; Sierra-Honigmann et al.,
1996; Hirabayashi et al., 1999). In many of these cell mod-
els cPLA2 translocates to the nuclear envelope and endo-
plasmic reticulum in response to cell stimulation, although
exceptions have been observed. In confluent endothelial
cells treated with histamine, cPLA2 translocates to both
the nuclear envelope and to the plasma membrane at in-
tercellular junctions (Sierra-Honigmann et al., 1996). A
punctate clustering of cPLA2 has been observed in the cy-
toplasm of mouse 3T3 fibroblasts overexpressing the epi-
dermal growth factor receptor, and this distribution is not
influenced by epidermal growth factor or calcium iono-
phore (Bunt et al., 1997). A punctate cytoplasmic localiza-
tion of cPLA2 occurs in U937 cells and appears to be due
to association with cytoplasmic lipid bodies (Yu et al.,
1998).
The Role of Phosphorylation in cPLA2 Activation
in Sf9 Cells
Using a variety of agonists that act on cells by diverse
mechanisms, it has become clear that there are alternative
regulatory pathways that can lead to activation of cPLA2
and arachidonic acid release (Leslie, 1997). The ability of
okadaic acid to activate cPLA2 and induce arachidonic
acid release in macrophages and Sf9 cells without increas-
ing intracellular calcium provides a useful tool to elucidate
novel mechanisms involved in cPLA2 regulation. Previous
work in macrophages and other cell models has demon-
strated that phosphorylation on S505 is not sufficient for
activation of cPLA2 and arachidonic acid release in the ab-
sence of an increase in intracellular calcium (Lin et al.,
1992; Qiu et al., 1998). This is also evident in Sf9 cells since
a significant portion of cPLA2 is constitutively phosphory-
lated on S505 when expressed in Sf9 cells, yet there is no
arachidonic acid release unless the cells are treated with
okadaic acid or agonists that increase intracellular calcium
(Abdullah et al., 1995; de Carvalho et al., 1996). This im-
plicates an alternative mechanism in the regulation of
cPLA2 in response to okadaic acid. One possibility was a
role for S727 phosphorylation which is preferentially in-
duced in okadaic acid–treated Sf9 cells (de Carvalho et al.,
1996). S505, S437, and S454 are constitutively phosphory-
lated on cPLA2 in unstimulated Sf9 cells, and their phos-
phorylation state is increased only modestly in response to
agonist treatment. These four residues represent the only
major phosphorylation sites on cPLA2 in okadaic acid–
treated Sf9 cells. Whether phosphorylation of these novel
sites, particularly S727, plays a functional role in cPLA2
activation has been an important question. The mutagene-
sis data demonstrate that okadaic acid–induced phosphor-
ylation of cPLA2 on S727, S437, or S454 plays no func-
tional role in cPLA2-mediated arachidonic acid release in
this model. Whether phosphorylation of S727 plays a func-
tional role in cPLA2 regulation in other cells where it
has been identified remains to be established (Börsch-
Haubold et al., 1998). Phosphorylation of S505 does play a
role in augmenting arachidonic acid release by both oka-
daic acid and the calcium-mobilizing agonists. However, it
is not absolutely essential since Sf9 cells expressing cPLA2
containing the S505A mutation still release arachidonic
acid to z50% of the level of Sf9 cells expressing wild-type
cPLA2. The role played by S505 phosphorylation in the
regulation of cPLA2 appears to be cell type– and agonist-
dependent. In macrophages, S505 phosphorylation is not
essential for arachidonic acid release in response to ago-
nists that induce a sustained increase in intracellular cal-
cium but does appear to be required when there is only a
transient increase in calcium (Qiu et al., 1998). In CHO
cells overexpressing cPLA2, S505 phosphorylation is es-
sential for agonist-induced arachidonic acid release (Schie-
vella et al., 1995). However, S505 phosphorylation of
cPLA2 is not required for arachidonic acid release in
thrombin-stimulated platelets (Kramer et al., 1996).
Figure 9. GFP-C2 translocates to the nuclear envelope in Sf9
cells treated with A23187 but not okadaic acid. Sf9 cells express-
ing a GFP-C2 domain fusion protein were incubated with 2 mg/ml
A23187 (left) or 1 mM okadaic acid (right) for the times indicated
(in minutes). Images were obtained with a digital confocal mi-
croscopy system.Gijn et al. Regulation of Cytosolic PLA2 1229
The Role of the C2 Domain in cPLA2 Regulation
Our translocation results show a steady accumulation of
GFP-cPLA2 in the perinuclear region of Sf9 cells after ad-
dition of A23187 or CryIC toxin. This observation is con-
sistent with recent data showing that a sustained increase
in the intracellular calcium concentration is required for
the stable association of cPLA2-GFP to the nuclear
envelope of CHO cells, which correlates with agonist-
induced arachidonic acid release (Hirabayashi et al.,
1999). Although okadaic acid does not increase intracel-
lular calcium, our results demonstrate a requirement for
a functional C2 domain. Mutagenesis of calcium-binding
residues D43 and D93 in the C2 domain quantitatively
suppress okadaic acid–induced arachidonic acid release
and translocation of cPLA2 to the nuclear envelope. In ad-
dition, lowering the levels of intracellular calcium by in-
cluding EGTA in the medium diminished okadaic acid–
induced arachidonic acid release, suggesting a requirement
for the resting levels of calcium. Attempts to completely
chelate intracellular calcium by also including BAPTA or
Quin-2 were unsuccessful due to adverse effects on Sf9
cells. The differences in the functional responses of Sf9
cells expressing the D43N and D93N mutant enzymes sug-
gest that these mutations differentially affect the affinity
of the enzyme for calcium. This is consistent with the
structural analysis of the cPLA2 C2 domain, which binds
two calcium ions with different affinities (Nalefski et al.,
1997; Perisic et al., 1998; Xu et al., 1998; Bittova et al.,
1999). D43 forms one interaction with each of the two cal-
cium ions, whereas both side chain oxygens of D93 partici-
pate in binding only one of the calcium ions at site II. It
has been shown recently that purified cPLA2 containing
D43N and D93N mutations exhibits greatly diminished
PLA2 activity and binding to phospholipids as compared
with the wild-type enzyme (Bittova et al., 1999). The cal-
cium requirements are higher for cPLA2 containing the
D43N mutation than D93N, consistent with the functional
differences we observe in the Sf9 model. Differential roles
for calcium binding residues in the C2 domain of PKCa
have also been reported (Medkova and Cho, 1998). D246
plays the most critical role for PKCa activation and cal-
cium-dependent binding to lipid vesicles in vitro, and is
thought to be due to its ability to coordinate two Ca21 ions
tightly. Our results demonstrate a pivotal role for D43 in
mediating cPLA2 translocation in intact cells. cPLA2 con-
taining the D43N mutation is unable to translocate to the
nuclear envelope or to mediate arachidonic acid release in
response to okadaic acid, which acts at resting levels of cal-
cium (60–70 nM), but also in response to calcium-mobiliz-
ing agonists A23187 and CryIC toxin, which increase intra-
cellular calcium to z0.6 mM calcium. In contrast, cPLA2
containing the D93N mutation translocates and releases
arachidonic acid at intracellular calcium in the 0.2–0.6 mM
range but not at resting calcium. This difference in affinity
of the mutant cPLA2 enzymes is also evident when as-
sayed in vitro. However, the mutations do not adversely
affect the conformation of the active site since they all
have significant enzymatic activity when assayed in vitro at
millimolar calcium, and they exhibit similar lysophospholi-
pase activity as the wild-type enzyme.
The Role of the C2 Domain in Nuclear Localization
of cPLA2
The mechanisms involved in the preferential targeting of
cPLA2 to the nuclear envelope are not known. However,
an important observation from this study is that the C2 do-
main of cPLA2 translocates to the nuclear envelope in re-
sponse to the calcium-mobilizing agonists. This suggests
that the sequence determinants for this preferential local-
ization reside in the C2 domain. The C2 domain of cPLA2
has been shown to preferentially bind to phosphatidylcho-
line headgroups (Nalefski et al., 1998). However, this
would not be expected to be responsible for nuclear tar-
geting since phosphatidylcholine is found in all cellular
membranes. The C2 domain of Nedd4 also exhibits prefer-
ential binding to phosphatidylcholine but has been shown
recently to translocate to the plasma membrane in cells
treated with calcium ionophore (Plant et al., 1997). Al-
Figure 10. Extracellular cal-
cium is required for transloca-
tion of GFP-C2 and GFP-cPLA2
in Sf9 cells. Sf9 cells expressing
GFP-cPLA2 (left series) or
GFP-C2 (right series) were
treated with 2 mg/ml A23187 or
2 mg/ml CryIC toxin in TNM-
FH medium containing 10 mM
EGTA. After a 15-min incuba-
tion, calcium chloride was added
(final concentration of 9 mM),
and cells were incubated for an
additional 10 min. Images were
obtained with a digital confocal
microscopy system.The Journal of Cell Biology, Volume 145, 1999 1230
though the C2 domains of Nedd4 and cPLA2 have similar
properties including the same topology (topology II),
similar affinities for calcium, and preference for binding
amphipathic phospholipid, they exhibit considerable se-
quence diversity that may be responsible for their dif-
ferences in subcellular localization. The C2 domain of
PKCa, which binds phosphatidylserine, has been shown
recently to bind to the plasma membrane when expressed
in COS cells (Corbalán-García et al., 1999). The mem-
brane binding of the PKCa C2 domain occurs at resting
levels of calcium, consistent with its higher affinity for cal-
cium for binding to phospholipid vesicles as compared
with the cPLA2 or the Nedd4 C2 domains (Nalefski et al.,
1997; Hixon et al., 1998; Corbalán-García et al., 1999).
Results of several recent in vitro studies have begun to
shed light on the mechanisms involved in interaction of
the C2 domain and full-length cPLA2 with phospholipid
vesicles. Experiments have shown that the three calcium-
binding loops are involved in the binding of the isolated
C2 domain to phosphatidylcholine vesicles (Nalefski and
Falke, 1998). These results are consistent with the obser-
vation that the two Ca21 ions bound to the C2 domain be-
come occluded, and dissociate more slowly upon binding
of the C2 domain to phospholipid vesicles (Nalefski et al.,
1997). Regions of the cPLA2 C2 domain that interact with
phospholipid micelles have also been identified by 15N-
HSQC spectroscopy revealing a role for the calcium-bind-
ing loops, proximal ends of attached b strands, and por-
tions of b strands 2 and 3 (Xu et al., 1998). It has been
shown recently that calcium induces not only binding but
penetration of cPLA2 and the C2 domain into artificial
lipid membranes (Davletov et al., 1998; Lichtenbergova
et al., 1998). An important role for hydrophobic residues
in the interaction of the cPLA2 C2 domain with phospho-
lipid has been implicated from several studies (Davletov
et al., 1998; Lichtenbergova et al., 1998; Nalefski and
Falke, 1998; Nalefski et al., 1998; Bittova et al., 1999). The
residues F35, L39, Y96, and V97 in the calcium binding
loops 1 and 3 appear to be particularly important for phos-
pholipid binding and membrane penetration of the C2 do-
main of cPLA2 (Nalefski and Falke, 1998; Bittova et al.,
1999). Two tryptophan residues in the calcium-binding re-
gion 3 of PKCa C2 domain also have been shown recently
to be essential for binding phospholipid vesicles and mem-
brane penetration in vitro (Medkova and Cho, 1998). Mu-
tagenesis studies of the C2 domain of PKCbII have shown
that the calcium-induced interaction of PKC with mem-
brane is not due to charge neutralization of the acidic
residues (Edwards and Newton, 1997). However, unlike
cPLA2 and PKC in which hydrophobic interaction with
phospholipid plays a predominant role, the binding of the
C2A domain of synaptotagmin I to phospholipid is largely
electrostatic (Davletov et al., 1998; Zhang et al., 1998).
Contribution of Regions Other Than the C2 Domain of 
cPLA2 in Membrane Binding
Recent studies have demonstrated that the binding prop-
erties of the isolated C2 domain of cPLA2 do not necessar-
ily predict the binding properties of the full-length enzyme
(Hixon et al., 1998). Binding of the C2 domain to anionic
and zwitterionic phospholipid vesicles occurs with simi-
lar affinities and requires calcium. However, full-length
cPLA2 binds much tighter to anionic (phosphatidylmetha-
nol) than zwitterionic (phosphatidylcholine) vesicles and,
surprisingly, the binding to anionic vesicles does not
require calcium. Consequently, this implicates regions
downstream of the C2 domain in interacting with mem-
branes containing anionic phospholipids. There is evi-
dence that anionic phospholipids, particularly phospha-
tidylinositol-4,5-bisphosphate (PIP2), enhance enzymatic
activity and promote high affinity binding of cPLA2 to
phospholipid vesicles (Leslie and Channon, 1990; Buck-
land and Wilton, 1997; Mosior et al., 1998). Interestingly,
PIP2 enhances both calcium-dependent and -independent
binding and activity of cPLA2 and may represent a physio-
logical equivalent of phosphatidylmethanol (Hixon et al.,
1998; Mosior et al., 1998).
Our results demonstrate that the C2 domain of cPLA2
can translocate to the nuclear envelope in response to cal-
cium-mobilizing agonists but not in response to okadaic
acid. This provides evidence in the intact cell that another
region of cPLA2 may also be involved in membrane tar-
geting induced by agonists that do not increase intracellu-
lar calcium. However, mutating calcium-binding residues
in the C2 domain of cPLA2 and depletion of intracellular
calcium suppress okadaic acid–induced arachidonic acid
release indicating a requirement for the C2 domain and
resting levels of calcium for translocation. These data sug-
gest that cPLA2 translocation to membrane induced by
okadaic acid may be coordinately regulated by the C2 do-
main and another region of the enzyme. The cooperative
regulation of membrane association by two domains has
been observed in numerous proteins including cytohesin-1,
Tiam1, Ras-GRF, and phospholipase C, to name a few
(Buchsbaum et al., 1996; Williams and Katan, 1996; Stam
et al., 1997; Nagel et al., 1998). Membrane binding of phos-
pholipase Cd1 has been studied extensively, and appears
to involve a cooperative role for the PH, C2, and catalytic
domains (Williams and Katan, 1996).
Our results demonstrate that the effects of the C2 do-
main mutations on the ability of cPLA2 to mediate arachi-
donic acid release correlate directly with their ability to
translocate to the nuclear envelope. In addition, a differ-
ential functional role is shown for specific calcium-binding
residues in the C2 domain in cPLA2 regulation in intact
cells. A functional C2 domain is required for agonist-
induced translocation of cPLA2 and arachidonic acid re-
lease in the Sf9 model even with okadaic acid, which acti-
vates cPLA2 without increasing intracellular calcium. This
suggests that binding of the C2 domain to calcium, even at
resting levels, may be required for stable association of the
enzyme with the membrane. Interestingly, okadaic acid in-
duces translocation of the full-length cPLA2, but not the
C2 domain. Our results indicate that the C2 domain is nec-
essary and sufficient for cPLA2 translocation to the nu-
clear envelope in response to calcium-mobilizing agonists.
However, a functional C2 domain is necessary but not suf-
ficient for translocation in response to okadaic acid, sug-
gesting that additional regions of the enzyme are also in-
volved.
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